Published in Cancer Lett on November 11, 2004
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J (2006) 2.38
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol (2008) 2.28
A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol (2011) 2.11
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer (2008) 1.83
Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol (2012) 1.77
Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours. Br J Cancer (2008) 1.74
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther (2009) 1.73
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog (2008) 1.68
Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev (2010) 1.63
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer (2007) 1.53
Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res (2010) 1.51
Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol (2008) 1.48
Molecular functions of syndecan-1 in disease. Matrix Biol (2011) 1.47
Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem (2011) 1.45
Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A (2016) 1.42
Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci U S A (2010) 1.37
MET as a target for treatment of chest tumors. Lung Cancer (2008) 1.29
Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. Exp Cell Res (2007) 1.22
Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc Natl Acad Sci U S A (2006) 1.18
MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer (2010) 1.16
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist (2011) 1.15
Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res (2008) 1.15
The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Diagn Pathol (2012) 1.14
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther (2007) 1.14
Targeting MET Amplification as a New Oncogenic Driver. Cancers (Basel) (2014) 1.11
Cancer biomarkers: are we ready for the prime time? Cancers (Basel) (2010) 1.10
MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol (2011) 1.10
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther (2008) 1.07
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem (2008) 1.06
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res (2011) 1.04
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther (2008) 1.04
Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med (2010) 1.03
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer (2009) 1.03
Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol (2010) 1.01
Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia (2009) 1.01
Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol (2009) 1.00
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid (2013) 0.99
Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res (2012) 0.99
Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med (2007) 0.98
c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer (2007) 0.98
Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets (2012) 0.97
The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res (2009) 0.96
Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther (2009) 0.96
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. Cell Signal (2007) 0.96
Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist. Proc Natl Acad Sci U S A (2007) 0.95
Ubiquitination-dependent regulation of signaling receptors in cancer. Genes Cancer (2010) 0.94
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2011) 0.93
Ancillary testing in lung cancer diagnosis. Pulm Med (2012) 0.92
c-Met as a Target for Personalized Therapy. Transl Oncogenomics (2015) 0.92
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer (2014) 0.92
From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells. Int J Oncol (2013) 0.92
Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia (2006) 0.91
Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci (2016) 0.91
Heterogeneous kinetics of AKT signaling in individual cells are accounted for by variable protein concentration. Front Physiol (2012) 0.89
Antibody discovery via multiplexed single cell characterization. J Immunol Methods (2008) 0.88
c-Met inhibitors. Infect Agent Cancer (2013) 0.87
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. Cancer Res (2015) 0.87
c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death. Mol Med (2012) 0.87
Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep (2015) 0.86
Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition. Clin Cancer Res (2013) 0.86
Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med (2008) 0.86
Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation. Biochemistry (2008) 0.86
Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma. BMC Res Notes (2014) 0.86
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor. Cancer Sci (2014) 0.86
PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor. J Nucl Med (2015) 0.85
Recent discoveries in the genetics of melanoma and their therapeutic implications. Arch Immunol Ther Exp (Warsz) (2007) 0.85
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. Br J Cancer (2014) 0.85
Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy. Mol Cancer Ther (2011) 0.84
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). Oncotarget (2015) 0.84
Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas. Sci Rep (2016) 0.83
Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development. PLoS One (2014) 0.83
Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy? Cancer Cell Int (2016) 0.83
Characterization of a human cell line stably over-expressing the candidate oncogene, dual specificity phosphatase 12. PLoS One (2011) 0.82
The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) (2014) 0.82
The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells. J Biol Chem (2012) 0.82
Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets. Oncotarget (2015) 0.82
Critical signal transduction pathways in CLL. Adv Exp Med Biol (2013) 0.81
Specific and nontoxic silencing in mammalian cells with expressed long dsRNAs. Nucleic Acids Res (2006) 0.81
(-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch Biochem Biophys (2010) 0.80
Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. Oncotarget (2015) 0.80
Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res (2013) 0.80
Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest New Drugs (2010) 0.80
Germline mutations causing familial lung cancer. J Hum Genet (2015) 0.79
Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors. J Mol Model (2011) 0.79
The Blocking of c-Met Signaling Induces Apoptosis through the Increase of p53 Protein in Lung Cancer. Cancer Res Treat (2012) 0.79
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer (2015) 0.78
Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacol Sin (2013) 0.78
The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms? Cancers (Basel) (2014) 0.77
Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma. Am J Pathol (2011) 0.77
Selection and optimization of asymmetric siRNA targeting the human c-MET gene. Mol Cells (2011) 0.77
Development of Tivantinib as Treatment for Hepatocellular Carcinoma. J Clin Transl Hepatol (2013) 0.77
Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility. PLoS One (2015) 0.77
Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621. MAbs (2012) 0.76
Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma. Neoplasia (2006) 0.76
A synthetic biology-based device prevents liver injury in mice. J Hepatol (2016) 0.76
Future directions in the evaluation of c-MET-driven malignancies. Ther Adv Med Oncol (2011) 0.76
Detection of estrogen-independent growth-stimulating activity in breast cancer tissues: implication for tumor aggressiveness. Cancer Microenviron (2013) 0.76
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res (2003) 3.47
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39
The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev (2004) 2.23
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov (2011) 2.22
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev (2002) 2.08
c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res (2007) 2.06
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2011) 1.99
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res (2002) 1.84
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood (2004) 1.81
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J (2012) 1.80
Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 1.79
Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res (2004) 1.69
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog (2008) 1.68
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res (2006) 1.64
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res (2006) 1.61
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res (2008) 1.60
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res (2007) 1.59
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol (2006) 1.55
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem (2007) 1.53
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg (2012) 1.51
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res (2005) 1.50
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep (2007) 1.50
Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys (2002) 1.49
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg (2010) 1.46
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem (2001) 1.45
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol (2008) 1.41
Fyn: a novel molecular target in cancer. Cancer (2010) 1.40
Lung carcinoma in African Americans. Nat Clin Pract Oncol (2007) 1.33
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol (2010) 1.31
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol (2008) 1.29
MET as a target for treatment of chest tumors. Lung Cancer (2008) 1.29
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem (2010) 1.27
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 1.26
MET as a possible target for non-small-cell lung cancer. J Clin Oncol (2013) 1.25
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One (2010) 1.25
FYN is overexpressed in human prostate cancer. BJU Int (2008) 1.22
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res (2007) 1.19
Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets (2005) 1.16
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev (2008) 1.14
A novel classification of lung cancer into molecular subtypes. PLoS One (2012) 1.13
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol (2010) 1.12
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2002) 1.12
Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg (2012) 1.11
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res (2004) 1.11
The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol (2011) 1.11
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol (2014) 1.09
Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. J Clin Pathol (2010) 1.08
The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist (2009) 1.07
MET pathway as a therapeutic target. J Thorac Oncol (2009) 1.06
PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res (2010) 1.06
Tyrosine kinase mutations in human cancer. Curr Mol Med (2007) 1.05
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer (2008) 1.05
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res (2011) 1.05
Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology (2012) 1.05
Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. J Mol Diagn (2013) 1.04
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest (2009) 1.04
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res (2002) 1.04
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res (2009) 1.03
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol (2007) 1.03
Targeting c-Kit mutations: basic science to novel therapies. Leuk Res (2004) 1.03
A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. J Biol Chem (2002) 1.03
Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther (2011) 1.02
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol (2007) 1.01
Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue. Clin Proteomics (2012) 1.01
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol (2009) 1.01
MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr (2010) 1.00
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res (2011) 0.98
The MET axis as a therapeutic target. Update Cancer Ther (2009) 0.98
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer (2013) 0.97
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. Cell Signal (2007) 0.96
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res (2013) 0.96
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol (2008) 0.95
Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. Cancer Res (2005) 0.95
Generation of comprehensive thoracic oncology database--tool for translational research. J Vis Exp (2011) 0.94
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem (2014) 0.94
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res (2012) 0.93
EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal (2008) 0.93
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther (2008) 0.92
Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res (2003) 0.92
Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrom Rev (2007) 0.92
Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity. J Biol Chem (2012) 0.91